Artificial Life Announces Second Healthcare iPhone/iPad App

LOS ANGELES and HONG KONG, Jan. 20, 2011 /PRNewswire-Asia/ -- Artificial Life, Inc., (OTC Bulletin Board: ALIF) (http://www.artificial-life.com), a leading provider of award-winning mobile technology and applications, announced today their upcoming mobile telemedicine health solution, NeuroDerMo, the second in a series of mobile healthcare products. The name "NeuroDerMo" is short for Neurodermatitis + Mobile. Neurodermatitis is a serious skin condition that will be monitored and managed by the application through inputs by patients and caregivers.

Research shows that six percent of the world's population is suffering from some form of neurodermatitis and that its prevalence globally is on the rise*. This skin disorder may be associated with other medical conditions such as psychological disorders, depression anxiety, nervousness eczema and/or psoriasis. It can also be exacerbated by chronic scratching and is common in children*.

NeuroDerMo is launched as a management solution for this segment of the population suffering from neurodermatitis and can be used as an aid in the successful treatment of the condition. This product leverages Artificial Life 's (ALIF) OPUS-M™ platform for end-consumers, healthcare providers and healthcare businesses. NeuroDerMo is scheduled for commercial availability in early Q2 2011. The product follows the Company's successful launch of their first healthcare monitoring mobile application GluCoMo™, a diabetes monitoring mobile application on the iPhone and iPad.

Introducing NeuroDerMo

The NeuroDerMo app is a mobile telemedicine and healthcare solution allowing patients, caregivers, doctors, and hospitals to share and communicate through mobile mediums such as smartphones, tablets, netbooks and other mobile internet devices.  The goal is to track changes in skin conditions by closely monitoring many variables (such as redness, itchiness, etc.) which is facilitated by mobile data sharing and smart back-end processes. The NeruoDerMo app will enable remote and real-time monitoring and management of patients by doctors and hospitals with enhanced healthcare services which can result in a reduction in administration costs.  NeuroDerMo offers an easily accessible repository of monitoring data for the neurodermatitis condition for patients to share with friends, families and caregivers.

NeruoDerMo has a customized mobile device front-end client and portal as well as a custom back-end infrastructure supported by Artificial Life's m-commerce solution OPUS-M™:

Front-end

The NeuroDerMo front-end is comprised of two parts, a mobile client and a web portal. The mobile client is able to support most major smartphone platforms; allowing users to keep track of relevant information in real time such as wound condition tracking, food and medication intake and more. A photo diary with camera snapshots of affected areas gives users a chronological visual diary of their condition history. Sharing of information is also simplified and promoted through online social communities and forums so that users can quickly share their latest medical status, wound conditions, and other medical information with others. For greater flexibility and convenience, a synchronized web portal is also available for users and their friends, family members, and caregivers.

Back-end

The NeuroDerMo back-end is powered by Artificial Life's OPUS-M™ technology and allows for friends, families, and caregivers to share critical information with each other.

Business Model

The front-end mobile client of NeuroDerMo will initially be launched as a free mobile app and service with limited features. Depending on the needs of the users, additional premium features and functions for the mobile client can then be purchased inside the mobile app in the coming versions.

NeuroDerMo will soon also be offered as a white label solution and can be adopted by doctors, health clinics, hospitals and/or healthcare industry businesses. The pricing of the customization, integration and maintenance services are based on monthly rental and usage fees.

"Artificial Life further expands its telemedicine health app portfolio with our upcoming launch of NeuroDerMo, a powerful mobile monitoring solution for patients suffering from neurodermatitis. We plan to grow more in the telemedicine field and will soon expand our healthcare app portfolio to include a wide-ranging family of mobile monitoring apps available across many smartphone platforms," said Eberhard Schoneburg, CEO of Artificial Life, Inc.

*Source: Schäfer, Günther N. Psoriasis - Neurodermatitis, Atopic Eczema Answers to Everyday Questions from A - Z. [Bad Säckingen]: G. N. Schäfer, 2006. Print.
Reitamo, S., Thomas A. Luger, and Martin Steinhoff. Textbook of Atopic Dermatitis. London: Informa Healthcare, 2008. Print.

*iPhone and iPad are trademarks of Apple Inc., registered in the U.S. and other countries.

About Artificial Life, Inc.

Artificial Life, Inc. has been a pioneer in artificial intelligence and mobile technology since its inception in Boston in 1994. We are a public US corporation (OTC BB: ALIF) with listing on the Frankfurt Stock Exchange (Frankfurt: AIF.F; Xetra: AIF.DE) and headquarters in Hong Kong. Our production center is in Hong Kong and we have additional offices in Berlin, Germany (EMEA headquarters) and Tokyo, Japan. As a leading provider of broadband mobile content and technology solutions in the world, we develop and sell a wide range of mobile applications for 3G, 3.5G and 4G network-enabled mobile (smart) phones. Currently our main business areas are: high quality 3D interactive (massive multiplayer) mobile games, mobile participation television, mobile business applications and our mobile commerce technology platform OPUS-M. We are supporting all major mobile phone operating systems and platforms. Recognized internationally for outstanding content quality and technology we have received many international awards and have been ranked one of the fastest growing companies in Asia Pacific by Deloitte.

For more information about Artificial Life, Inc., please visit our website www.artificial-life.com or our product websites: www.botme.com, www.mopa-tv.com, www.opus-m.com, www.glucomo.com, www.greencortex.com .

Facebook: http://www.botme.com/ref/alife-fb

Twitter: http://twitter.com/alifegames

MySpace: http://www.myspace.com/artificial_life_inc

Youtube: http://www.youtube.com/user/alifegames

Forward-Looking Statements:

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding our future results of operations, financial condition and business prospects. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue" or the negative of these terms or other comparable terminology. Although such statements are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on them. These statements involve risks and uncertainties, and actual market trends or our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied in these forward looking statements for a variety of reasons. Potential risks and uncertainties include, but are not limited to, our ability to obtain additional funding to operate and grow our business; the unproven potential of our mobile gaming business model; changing consumer preferences and uncertainty of market acceptance of our products; timely adoption and availability of 3G mobile technology; market acceptance for use of mobile handheld devices to play the interactive games; unpredictable mobile game development schedules; our reliance on a relatively small number of brands; our ability to license brands from others; our dependence upon resellers and telecommunication carriers and operators to distribute our products; our ability to successfully develop, introduce, and sell new or enhanced products in a timely manner; and the timing of new product announcements or introductions by us or by our competitors. For additional discussion of these risks and uncertainties and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB filed on March 16, 2010. We assume no obligation to update any forward-looking statements, which apply only as of the date of this press release.

For more information on ARTIFICIAL LIFE, INC., please contact:

SOURCE Artificial Life, Inc.